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Introduction
Although often overlooked, the preoperative 
characterization of an adnexal mass is of crucial 
importance for selecting the optimal management 
strategy. Firstly, accurate differentiation between 
benign and malignant tumors can lead to referral of 
patients with malignant tumors to gynecological 
oncology centers for further diagnosis or staging, 
followed by debulking surgery and/or administration 
of systemic therapy. This is an important factor that 
positively influences prognosis (Earle et al., 2006; 
Engelen et al., 2006; Woo et al., 2012; Bristow et 
al., 2013). Benign ovarian masses can be managed 
expectantly or by conservative surgical management 
with reduced morbidity and fertility preservation 
(Carley et al., 2002). Secondly, optimal treatment of 
adnexal malignancies depends on the type of tumor. 
Borderline tumors can be treated with less aggressive 
techniques than invasive tumors, which is of interest 
when fertility preservation is desired (Tinelli et 
al., 2006; Daraï et al., 2013). Furthermore, stage I 
ovarian cancer may be managed more conservatively 
than stage II-IV disease (Trimbos et al., 2003). 
Finally, for cancers of other primary origin 
metastasized to the ovary, treatment depends on the 
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All gynecologists are faced with ovarian tumors on a regular basis, and the accurate preoperative diagnosis of these 
masses is important because appropriate management depends on the type of tumor. Recently, the International 
Ovarian Tumor Analysis (IOTA) consortium published the Assessment of Different NEoplasias in the adneXa 
(ADNEX) model, the first risk model that differentiates between benign and four types of malignant ovarian tumors: 
borderline, stage I cancer, stage II-IV cancer, and secondary metastatic cancer. This approach is novel compared to 
existing tools that only differentiate between benign and malignant tumors, and therefore questions may arise on 
how ADNEX can be used in clinical practice. In the present paper, we first provide an in-depth discussion about 
the predictors used in ADNEX and the ability for risk prediction with different tumor histologies. Furthermore, we 
formulate suggestions about the selection and interpretation of risk cut-offs for patient stratification and choice of 
appropriate clinical management. This is illustrated with a few example patients. We cannot propose a generally 
applicable algorithm with fixed cut-offs, because (as with any risk model) this depends on the specific clinical setting 
in which the model will be used. Nevertheless, this paper provides a guidance on how the ADNEX model may be 
adopted into clinical practice.
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the managing clinician following local protocols. 
Exclusion criteria were refusal for transvaginal 
ultrasonography, pregnancy at the time of presen-
tation and surgical intervention more than 120 days 
after the ultrasound examination. If a patient 
presented with multiple masses, the mass with the 
most complex morphology on ultrasound exami-
nation was selected for analysis. If more than one 
mass with similar morphology was present, the 
largest or the most easily accessible mass was used. 
The model was developed on 3506 patients recruited 
between 1999 and 2007, temporally validated on 
2403 patients recruited between 2009 and 2012, and 
then updated on all 5909 patients in the final 
analysis. Twenty-four centers in 10 countries were 
involved (Van Calster et al., 2014).
Selection of predictors
The ADNEX model consists of three clinical 
predictors and six ultrasound predictors. The clinical 
predictors are age (years), serum CA-125 (U/mL) 
and type of center to which the patient has been 
referred for ultrasound examination. Type of center 
has been divided into oncology centers versus other 
hospitals, and is further discussed in the next section. 
The ultrasound predictors are the maximal diameter 
of the lesion (mm), proportion of solid tissue (%), 
type of tumor. Recently, the International Ovarian 
Tumor Analysis (IOTA) group proposed the 
Assessment of Different NEoplasias in the adneXa 
(ADNEX) model. This is the first risk model to 
differentiate between benign, borderline tumors, 
stage I invasive, stage II-IV invasive ovarian cancer 
and secondary metastatic cancer (Van Calster et al., 
2014). Such a ‘multiclass’ or polytomous model is 
uncommon and poses new practical challenges. The 
aim of this paper is to discuss the ADNEX model in 




The ADNEX model was developed and validated 
using data from the IOTA phase 1-3 datasets, 
consisting of prospectively collected patients who 
were referred for an ultrasound examination to one 
of the participating centers for a known or a 
suspected adnexal mass (Timmerman et al., 2005; 
Van Holsbeke et al., 2009; Van Calster et al., 2012; 
Kaijser et al., 2014). Patients were eligible for 
inclusion if they presented with at least one adnexal 
mass that was judged not to be a physiological cyst, 
and if they were selected for surgical intervention by 
Fig. 1. — Ultrasound characteristics selected as predictors in the ADNEX model
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Type of center
One of the ADNEX predictors is the type of center, 
divided into oncology centers and other hospitals. 
An ‘oncology center’ was defined as a tertiary 
referral center with a specific gynecological 
oncology unit. The prevalence of different types of 
malignant tumors is higher in oncology centers 
compared to other centers (Table I). Using the data 
on all 5909 patients, we observed malignancy rates 
between 22 and 66% in oncology centers, and 
between 0 and 30% in other centers (Van Calster 
et al., 2014). This is largely explained by the 
observation that patients with masses that look 
suspicious are more often referred to specialized 
centers for assessment and treatment. Nevertheless, 
although the ADNEX model contains eight patient 
or tumor-specific predictors, type of center was still 
predictive (Van Calster et al., 2014).
If the same patient would be evaluated at a local 
community hospital and then also by a clinician in 
an oncology center, the risk of malignancy for the 
same tumor would be higher in the latter setting than 
in the former. Intuitively this might sound confusing, 
but as Candido-dos-Reis (2014) stated, type of 
center may still be a surrogate for clinical signs of 
malignancy that are not in the ADNEX model. 
Potential examples can be symptoms for ovarian 
cancer, such as pain and bloating or mode of detec-
tion. This is an issue for further research. 
Note that type of center is the weakest of all nine 
ADNEX predictors (Van Calster et al., 2014). This 
implies that the higher baseline risks of malignant 
tumor types in oncology centers are largely (but not 
completely) explained by patient- and tumor-
specific predictors. Nonetheless, the inclusion of 
type of center is important to obtain more reliable 
risk predictions.
Reference standard
The reference standard for the ADNEX model was 
based on histopathological examination of excised 
number of papillary projections (0, 1, 2, 3, > 3), 
pres ence of more than 10 cyst locules (yes/no), 
acoustic shadows (yes/no), and presence of ascites 
(yes/no) (Fig. 1). The proportion of solid tissue is 
defined as the ratio of the maximal diameter of the 
largest solid component and the maximal diameter 
of the lesion.
The ADNEX predictors were selected as follows. 
Clinicians with experience in the characterization of 
adnexal tumors a priori selected a limited set of 
variables that were considered as potentially useful 
predictors. This was based on the variables’ perceived 
pre dictive value to distinguish between the four 
types of malignant ovarian pathologies of interest, 
subjectivity, dependency on the experience of the 
ultrasound examiner, and impact on the patient. 
This approach is in accordance with current meth-
odological recommendations (Steyerberg, 2009). In 
addition, variable selection was also based on an 
analysis of consistency of the variables across the 
IOTA study centers (Wynants et al., 2013). As a 
result, it was deliberately decided not to include 
color Doppler variables or the presence of cyst 
wall irregularities. Ten potential predictor variables 
were selected, on which further statistical variable 
selection was performed (Van Calster et al., 2014). 
This resulted in the omission of one variable (family 
history of ovarian cancer). As a result ADNEX 
contains nine predictors that have strong diagnostic 
value.
Six predictors in the ADNEX model are ultra-
sound variables. A concern might be the experience 
required to accurately measure these variables. 
However, there is now evidence available that 
suggests that ultrasound-based prediction models 
and rules retain their performance in the hands 
of relatively inexperienced doctors and sono-
graphers (Nunes et al., 2012; Alcazar et al., 2013; 
Sayasneh et al., 2013a; Sayasneh et al., 2013b) on 
the condition that the examiners are familiar with 
the IOTA terms and definitions and properly use the 
IOTA examination and measurement techniques 
(Timmerman et al., 2000). 
Table I. — Baseline risks for the different final diagnoses using the combined IOTA phase 1-3 dataset 
(n = 5909).
Overall Oncology center Other center
Benign 68.2% 48.8% 83.7%
Malignant 31.8% 51.2% 16.3%
Borderline 6.3% 9.3% 3.8%
Stage I invasive 7.4% 10.3% 4.6%
Stage II-IV invasive 14.1% 24.3% 6.4%
Secondary metastatic 4.0% 7.3% 1.6%
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characterize adnexal pathology, the IOTA logistic 
regression model LR2 (Timmerman et al., 2005; 
Van Holsbeke, 2012; Van Calster et al., 2012) and 
the IOTA ‘simple rules’(Timmerman et al., 2008; 
Timmerman et al., 2010) performed best for the 
overall discrimination between benign and all 
malignant masses (Kaijser et al., 2014). The 
ADNEX model seems to perform similar to, or even 
slightly better than, both LR2 (AUC 0.92) and 
simple rules (Testa et al., 2014).
Validation AUCs for discrimination between 
malignant subtypes varied between 0.71 and 0.95. 
The model discriminated well between stage I 
cancer and borderline tumors (validation AUC 0.75) 
and between stage I cancer and secondary metastatic 
cancer (validation AUC 0.71) (Van Calster et al., 
2014). It performed very well in distinguishing stage 
II-IV cancer from other malignancies (validation 
AUCs for stage II-IV cancer versus borderline 
tumors was 0.95, versus stage I cancer was 0.87, and 
versus secondary metastatic cancer was 0.82) (Van 
Calster et al., 2014). Finally, the validation AUC for 
borderline versus secondary metastatic cancer was 
0.87 (Van Calster et al., 2014).
It is interesting to look at the final histological 
outcome in relation to the average predicted risks for 
the five ADNEX groups because this illustrates the 
relative difficulty of classifying different types of 
adnexal masses (Fig. 2). As might be expected, 
tissue, and for malignant tumors also on surgical 
staging using the classification of the International 
Federation of Gynecology and Obstetrics (FIGO) 
(Prat, 2014). In the IOTA database, 21 histological 
groups were used (11 benign and 10 malignant 
groups) which were reduced to five for the ADNEX 
model: benign, borderline tumors, stage I invasive, 
stage II-IV invasive ovarian cancer and secondary 
metastatic cancer.
Risk prediction
When we consider the discrimination between 
benign and malignant adnexal masses, the area 
under the receiver operating characteristic cur-
ves (AUC) of the ADNEX model was 0.954 (95% 
confidence interval 0.947 to 0.961) on the develop-
ment data and 0.943 (0.934 to 0.952) on the valida-
tion data (Van Calster et al., 2014). Using a pre-
viously proposed cut-off of 10% (Timmerman et al., 
2005), the sensitivity for malignancy was 96.5% 
and specificity 71.3% on the validation data. The 
model discriminated well between benign tumors 
and each of four types of malignancy, with AUCs 
between 0.85 (benign versus borderline) and 0.99 
(benign versus stage II-IV cancer) (Van Calster et 
al., 2014).
In the most recent meta-analysis evaluating the 
performance of prediction models and rules to 
Fig. 2. — Average predicted risks for different histologies
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provide risk stratification could be the “golden 
standard” in optimizing patient-centered health care. 
Selecting cut-offs may be dependent on clinician, 
center, local protocols or guidelines.
For example, consider defining a risk cut-off for 
the selection of patients with benign masses for 
expectant management. Some centers will prefer the 
risk to be below 1%, while in other centers a cut-off 
of 5% may be chosen. On the other hand, referral 
to a tertiary oncology center for treatment of the 
most suspicious tumors by skilled gynecological 
oncologists may be more or less restricted. For one 
center it may be most important to have a high 
sensitivity, by choosing a low cut-off for malignancy 
(e.g. 5-10%). This leads to the appropriate referral 
of most malignancies to a gynecological oncologist. 
For another center, it may be more important to have 
a high specificity, by choosing a much higher cut-
off value for malignancy (e.g. 30%). This limits 
the number of false positive results, i.e. patients with 
benign pathology that are referred to the gyne-
cological oncologist. A wide spectrum of strategies 
could be encountered in different countries, with 
different health systems and referral protocols. 
Furthermore, once these cut-offs have been 
chosen, they should be interpreted for each indi-
vidual patient depending on her characteristics (e.g. 
age, history, comorbidity, operability, symptoms, 
fertility wish) and values. We will try to illustrate 
this in the next sections.
Benign versus malignant
When applying the ADNEX model for an individual 
patient, probabilities for a benign tumor and for four 
types of malignant tumors are obtained. When 
summing the latter four, the overall predicted risk of 
malignancy is obtained. As described above, the 
ADNEX model seems to discriminate at least as 
well between benign and malignant adnexal lesions 
as the simple rules or LR2. Note that future studies 
comparing ADNEX with other prediction models 
still have to confirm this finding. A center-specific 
cut-off value for relative risk stratification could be 
chosen for clinical management. When the patient’s 
risk is situated below the cut-off value, the mass 
can be considered as benign. Taking into account 
the patient’s values and symptomatology, con-
servative follow-up or laparoscopic cystectomy 
or adnex ectomy may be appropriate. Above the 
cut-off, the adnexal lesion may be considered 
suspicious enough for referral to a gynecological 
oncologist for appropriate treatment. In this second 
step, dif ferential diagnosis of the mass by the 
ADNEX model may help to optimize management 
(See 3.3).
benign teratomas and simple cysts were given the 
highest likelihood of being benign tumors. On 
average, the predicted probability of being benign 
was around 90% or higher for eight of eleven benign 
histologies. The ADNEX model had more dif-
ficulties with abscesses, rare benign tumors, and 
fibromas, with average predicted probabilities of 
being benign of around 70%. Regarding malignant 
masses, the average risk of being classified as an 
advanced stage cancer by the ADNEX model 
increased with FIGO stage. Conversely, the 
predicted risk of borderline or stage I ovarian cancer 
decreased with increasing FIGO stage. Finally, the 
average predicted risk of secondary metastatic 
cancer is highest for histo logically proven metastatic 
cancers, but notice that also fibromas, rare benign 
tumors and invasive ovarian cancers were assigned 
rather high risks of metastatic cancer. 
The final ADNEX model is available online and 
in mobile applications (www.iotagroup.org/
adnexmodel/). 
Clinical implications of the ADNEX model
As with any decision support tool, there does not 
exist a single fixed approach to use the model in 
clinical practice. Risk models aim to provide 
accurate risk estimates for individual patients. How 
these estimates are used to inform patients or make 
decisions depends on a multitude of factors, such as 
personal preferences, patient characteristics (e.g. 
age and co-morbidity), the patient’s values, local 
protocols and regional guidelines. In this section, we 
will discuss some general suggestions for using the 
ADNEX model in clinical practice. 
Cut-offs
Using risk predictions to guide patient stratification 
and treatment selection implies the introduction of 
cut-offs. The choice of cut-offs is not straightforward 
and may not be in accordance with modern evidence 
based medicine (EBM). Indeed, Greenhalgh and 
colleagues (2014), in their recent discussion of the 
EBM crisis stated that “inflexible rules and tech-
nology driven prompts may produce care that is 
management driven rather than patient centered” 
and that “real EBM demands individualized 
evidence, is characterized by expert judgment rather 
than mechanical rule following“ (Greenhalgh et al., 
2014). The rigid use of a cut-off may result in sub-
optimal and even unethical judgment. 
Nevertheless, instead of inflexibly using cut-offs 
both as a surrogate for clinical patient-centered 
decision making and as a generally applicable 
algorithm, a critical determination of cut-offs to 
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and 44.6% for being secondary metastatic cancer. 
Therefore, it is not realistic to expect that the 
predicted risk for being borderline, stage I cancer or 
secondary metastatic cancer could be as high as 
80%. This does not imply that the model does not 
function well: the AUCs for pairs of outcome 
categories were in fact quite high for a model that 
aims to differentiate between five categories. Rather, 
this finding may imply that the ADNEX model is a 
very interesting tool to assess whether there is an 
increased possibility of one of the more rare 
categories. In that sense, it is useful to check how 
the predicted risks for an individual patient compare 
with the baseline risks. For this purpose, the relative 
risk, i.e. absolute predicted risk divided by baseline 
risk, and their corresponding positive predictive 
value (PPV) can be computed (Table II). For 
example, patients with a relative risk of having a 
borderline tumor above 2 have an absolute predicted 
risk above 12.6%. In this subgroup of patients, 
23.9% were eventually diagnosed with a borderline 
tumor in our dataset.
The ADNEX model is the first known model able 
to discriminate between different types of malignant 
tumors, hence it is not straightforward how to use it 
clinically. In this respect knowledge of these relative 
risks as additional information to the predicted risks 
might help to adjust management to the individual 
patient. We believe that the aim should not be to 
classify tumors into a single subgroup of malignancy 
and to manage the patients accordingly. Rather, it is 
more sensible to assess per type of malignancy whether 
the predicted risk and/or relative risk is high or low.
Secondary metastases to the ovaries (Krukenberg 
tumors) originate in 76% of cases in the stomach, 
11% in the intestines (usually colon or rectum), 4% 
in the breast, 3% in the biliary system, 3% in the 
Note that the model is based on patients selected 
for surgery, with histopathological examination as 
standard reference. These patients in fact all had an 
indication for surgical intervention. This implies 
that the population on which the model was 
developed and validated is at higher risk than a 
population that includes patients who are selected 
for expectant management. This means that below 
the cut-off, the true risk of being malignant is 
expected to be even lower. 
In the future, once the model can be validated 
on populations including patients that are conser va-
tively followed (as in IOTA phase 5), better 
discrimination between benign and malignant 
tumors can probably be reached.
Differential diagnosis of malignancy: absolute risk 
versus relative change in risk
The ADNEX model calculates absolute risk 
estimates for four types of malignant tumors. These 
predicted risks for a specific patient can be an 
important result on which to base clinical mana-
gement. Of the four groups of malignant tumors, 
especially the secondary metastases to the ovaries 
and the borderline malignant ovarian tumors are of 
particular interest to identify preoperatively. 
However, due to the low prevalence of most malig-
nant outcome categories, predicted risks for these 
categories will not always be very high. As an 
example, secondary metastatic cancer has a baseline 
risk of only 4% (Table I). Hence it is more difficult 
to observe very high-predicted risks for this category 
compared to stage II-IV ovarian cancer (baseline 
risk 14.1%). We observed a maximum predicted 
risk of 68.4% for being borderline, 48.9% for being 
stage I cancer, 99.6% for being stage II-IV cancer, 
Table II. Relative risk of each tumor subgroup and corresponding positive predictive value (PPV) 
Relative risk
≤ 1 > 1 > 2 > 3 > 4
Borderline Absolute predicted risk ≤ 6.3 > 6.3 > 12.6 > 18.9 > 25.2
Observed PPV (%) 2.0 18.4 23.9 26.0 29.7
Stage I cancer Absolute predicted risk ≤ 7.4 > 7.4 > 14.8 > 22.2 > 29.6
Observed PPV (%) 2.2 16.5 21.2 26.6 30.7
Stage II-IV cancer Absolute predicted risk ≤ 14.1 > 14.1 > 28.2 > 42.3 > 56.4
Observed PPV (%) 1.4 56.5 66.2 71.3 75.8
Secondary Absolute predicted risk ≤ 4.0 > 4.0 > 8.0 > 12.0 > 16.0
metastatic cancer Observed PPV (%) 1.0 13.5 18.4 26.4 31.6
Relative risk: rate of change of the absolute predicted risk versus the baseline risk.
Observed PPV: the observed positive predictive value, i.e. the percentage of patients with a given outcome among those with a 
given relative risk for that outcome as observed in the sample of 5909 patients on which the final ADNEX coefficients were 
obtained. Note that this is an observed percentage that is unadjusted for clustering by center.
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The ADNEX model can also help the clinician to 
plan the appropriate strategy when invasive ovarian 
cancer is anticipated, but will probably contribute 
less here, as other imaging, surgical staging and 
patients’ characteristics will more strongly 
determine the suitable strategy.
Use of ADNEX with or without the CA-125 marker 
Although the ADNEX model includes the serum 
CA-125 level, the online and mobile applications 
allow for risk calculations without this information. 
If doing so, a warning is given “Calculate results 
without serum CA-125 level? The field is indeed 
optional but this will decrease the discrimination 
between Stage II-IV invasive tumors and the other 
malignancy subtypes”. A possible way to use 
ADNEX, especially when CA-125 is not always 
measured at your hospital, is by first applying the 
ADNEX model without serum CA-125 level and 
using these risk predictions to differentiate benign 
and malignant tumors. Results indicate that the 
omission of CA-125 has limited impact on 
discrimination between benign and all malignant 
tumors: the validation AUC was 0.943 with CA-125 
level included as a predictor, and 0.932 without 
using CA-125 level as a predictor (Van Calster et 
al., 2014). Second, in case of high (enough) risk of 
malignancy, the CA-125 level could be included to 
update risk predictions. This results in a superior 
differentiation between borderline, stage I invasive, 
stage II-IV invasive and secondary metastatic cancer 
(Van Calster et al., 2011, 2014). In this way, the 
measurement of the serum CA-125 level may be 




We assess a 59-year-old woman in a gynecological 
oncology center. The CA125 level is 153 U/ml. On 
transvaginal ultrasound, we describe a solid ovarian 
mass with a maximal lesion diameter of 59 mm, a 
maximal diameter of the largest solid component of 
59 mm as well, and without acoustic shadowing. 
There is presence of fluid outside the pouch of 
Douglas (ascites). If we introduce these parameters 
in the ADNEX model (in this case, application for 
smartphone), we obtain the results and column 
charts as illustrated in Figure 3. First we add the risk 
predictions for the four malignant subgroups to 
obtain the total risk of malignancy, which is 95.3% 
for this patient. Thus the tumor is likely to be 
malignant. Then, we look at the dif ferentiation 
appendix, and the remaining 3% in miscellaneous 
sites, such as pancreas, uterine cervix, urinary 
bladder (including urachus), and renal pelvis (Irving 
et al., 2006). When an ovarian malignancy is 
suspected on vaginal ultrasound, preoperative 
staging is planned by using chest x-ray, computed 
tomography (CT) of the abdomen, or magnetic 
resonance imaging (MRI) to evaluate the extension 
of the disease. When the ADNEX model would give 
an increased risk of secondary metastatic cancer 
(e.g. a relative risk > 3 or > 4, corresponding PPV 
26.4 and 31.6%), this could assist the clinician to 
plan appropriate diagnostics to exclude another 
primary origin of malignancy. Depending on 
the clinical situation these additional investiga-
tions could include a PET-CT, MRI whole body 
diffusion, gastroscopy, colonoscopy, and x-ray 
mammo graphy.
Borderline malignant epithelial tumors are 
primarily non-invasive but can (rarely) lead to 
invasive metastases. Extent of surgery depends on 
(surgical) staging and wish of fertility preservation 
(Cadron et al., 2007). If the latter is not desired by 
the patient, surgery consists of hysterectomy with 
bilateral adnexectomy, omentectomy and collection 
of peritoneal biopsies and cytology. If the patient 
wants to preserve her fertility, fertility sparing 
surgery (unilateral adnexectomy or cystectomy 
or unilateral adnexectomy with contralateral cyst-
ectomy if bilateral disease, with omentectomy and 
peritoneal biopsies) is possible. This procedure is 
usually done by laparotomy, but might also be done 
by laparoscopy. These fertility-sparing proce dures 
could be considered when the ADNEX model points 
to an increased risk for a borderline malignancy (e.g. 
a relative risk > 3 or > 4, corres ponding PPV 26.0 
and 29.7%).
The surgical treatment of invasive ovarian cancer 
stage I depends on the histology and degree of 
differentiation of the tumor (Vergote et al., 2001). 
Sex cord-stromal tumors and germ cell tumors 
can mostly be operated by fertility-sparing pro-
cedures. In the case of epithelial ovarian cancer, this 
depends on degree of differentiation or the 
histological type (e.g. expansile versus infiltrative 
invasive mucinous carcinoma) and is only possible 
in stage Ia (Muyldermans et al., 2013). In these 
patients, usually a laparotomy is performed with 
preoperative histopathological examination on 
frozen section. 
In the case of suspected advanced stage ovarian 
cancer, a diagnostic laparoscopy may be performed 
to assess feasibility of primary surgical debulking. 
The option of neo-adjuvant chemotherapy followed 
by debulking surgery might be preferred in certain 
circumstances (Vergote et al., 2010).
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Case 2
We evaluate a 48-year-old woman in a gyne co-
logical oncology center. She is diagnosed with a 
unilocular-solid adnexal mass with a maximal 
diameter of 66 mm. The maximal diameter of the 
largest solid component is 27 mm (one papillary 
projection), and there is no acoustic shadowing or 
ascites. CA125 is 22 U/ml. If we introduce these 
parameters in the ADNEX model using the 
smartphone application, we obtain the results and 
column charts as illustrated in Figure 4. The total 
risk of malignancy is 40.9%. The predicted risk for 
stage I ovarian cancer is 13.3% (compared to a 
baseline risk of 7.4%), the predicted risk for a 
borderline tumor is 18.7% (compared to a baseline 
risk of 6.3%). The predicted risks for the other 
subgroups are lower (5.9% for stage II-IV cancer 
and 3.0% for secondary metastatic cancer) and are 
also smaller than the baseline risks. The relative risk 
for stage I ovarian cancer and for a borderline tumor 
is 1.8 and 3, respectively. The relative risks for 
advanced stage ovarian cancer and secondary 
metastatic cancer are below 1. This patient was even-
tually diagnosed with a borderline ovarian tumor.
between four malignant subgroups and observe a 
predicted risk for secondary metastatic cancer of 
21.2% (compared to a baseline risk of 4.0%) and a 
risk for stage II-IV ovarian cancer of 67.9% 
(compared to a baseline risk of 14.1%). The 
predicted risks for the other subgroups are lower 
(4.6% for stage I cancer and 1.6% for borderline) 
and are also smaller than the baseline risks.
The corresponding relative risks (i.e. ratio of 
predicted risk and baseline risk) for secondary 
metastatic cancer and stage II-IV ovarian cancer are 
5.3 and 4.8, respectively. The relative risks for 
borderline or stage I ovarian cancer are below 1. 
With the knowledge of the increased risk for 
advanced stage ovarian cancer and more importantly 
secondary metastatic cancer, clinicians may adjust 
their preoperative diagnostics by excluding a tumor 
of other primary origin, such as gastric cancer 
or breast cancer. In case of a solid tumor 
these investigations may include PET-CT, MRI 
whole body diffusion, gastroscopy, colonoscopy, 
or mammo graphy. This is important as appropriate 
therapy depends on the origin of the primary tumor. 
This patient was eventually diagnosed with 
metastatic gastric cancer (Krukenberg tumor).
Fig. 3. — Illustration of the ADNEX model for case 1 Fig. 4. — Illustration of the ADNEX model for case 2
Van Calster.indd   39 26/03/15   10:16
40 FaCts VieWs Vis oBgyn
without CA-125 should this be desired, because 
results indicate no loss of performance in terms of 
AUC. Second, we can differentiate between the four 
subgroups of malignant tumors using the predicted 
risks for these subgroups. In this step, absolute 
predicted risks as well as the relative change of these 
risks versus the baseline risks provide clinically 
useful information to select an appropriate patient-
specific management strategy. We cannot propose a 
generally applicable algorithm with fixed cut-offs, 
because this depends on the specific clinical setting 
where the model will be used. Nevertheless, this 
paper provides guidance on how the ADNEX risk 
model may be adopted into clinical practice. 
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